Analysts Turned Bullish on These 10 Stocks on Tuesday

Page 3 of 3

4. Humana (NYSE:HUM)

Average Upside Potential: 32%

Bernstein raised its price target on Humana to $515 from $425 on November 17 and kept its Outperform rating. The firm said stable medical use and industry pricing discipline support a recovery in Medicare Advantage margins.

Humana sells Medicare Advantage and other health insurance plans and runs the CenterWell care business. In the third quarter of 2026, Humana reported GAAP earnings of $1.33 per share but an adjusted loss of $0.70 per share, against adjusted earnings of $3.24 a year earlier, as revenue grew. Humana reported those results on November 6, 2026. It raised its 2026 adjusted earnings guidance to at least $9.50.

On November 18, the Centers for Medicare & Medicaid Services proposed a rule that would tighten oversight of Medicare, Medicaid and the health insurance marketplace, with more audits of insurers and a way for the agency to recover improper payments, and Humana was among the insurers whose shares fell. Public comment on the proposal is open until January 19, 2027. We wrote about how Humana expects most of its members to be in four-star plans before that.

3. M-tron Industries (NYSEAMERICAN:MPTI)

Average Upside Potential: 34%

Freedom Broker analyst Sergey Glinyanov upgraded M-tron Industries to Buy from Hold on November 17 even as he cut his price target to $84 from $88, citing “lower valuation multiples and a higher discount rate.” He still raised his estimates for 2026 through 2028, with the biggest increase in 2028 on missile programs for Raytheon and Lockheed Martin.

M-tron makes frequency and spectrum control products, such as oscillators and filters, for aerospace and defense customers. Revenue in the third quarter of 2026 rose to $15.7 million, and backlog stood at $84.9 million on September 30, up from the end of 2025. M-tron reported those results on November 12, before Freedom Broker moved to Buy.

Glinyanov expects 2027 to be a transition year, with costs for added capacity and new hires weighing on results. He also sees the company’s radar business growing from under $2 million to about $8 million a year. Management cautioned that backlog could dip in the fourth quarter, which Freedom Broker attributed to contract timing rather than weaker demand. Freedom Broker also called the September 30 backlog a record high.

2. Cisco Systems (NASDAQ:CSCO)

Average Upside Potential: 35%

HSBC upgraded Cisco to Buy from Hold on November 17 and raised its price target to $133 from $120, pointing to growth in AI networking.

Cisco designs and sells the networking equipment and software that connect company and cloud data centers. In the first quarter of fiscal 2027, revenue rose 24% from a year earlier, and Chief Executive Officer Chuck Robbins said, “We are in the very early stages of a multi-year networking supercycle.” The company expects $9 billion in AI infrastructure revenue from hyperscalers in fiscal 2027, more than double the total for fiscal 2026. Product revenue grew faster than total revenue in the first quarter, which ended on October 24, 2026.

Robbins, who spoke when the company reported on November 12, also said the quarter brought Cisco’s strongest revenue and earnings per share growth in more than 15 years, and the company raised its fiscal 2027 non-GAAP earnings per share guidance to $5.47 to $5.53. Our analysis of whether Cisco can profit from helping customers spend less on AItakes up the other side of that demand.

1. Praxis Precision Medicines (NASDAQ:PRAX)

Average Upside Potential: 120%

Wells Fargo analyst Ben Burnett upgraded Praxis Precision Medicines to Overweight from Equal Weight on November 17 and raised his price target to $509 from $343. He said the company’s investor day on November 12 had eased his concerns about the endpoint in its ulixacaltamide trial.

Praxis develops treatments for brain disorders such as essential tremor and rare genetic forms of epilepsy. The FDA’s target decision date for relutrigine, which treats two types of developmental and epileptic encephalopathy, is December 27, 2026, and the date for ulixacaltamide, for essential tremor, is January 29, 2027. Chief Executive Officer Marcio Souza said, “We are entering a defining period for Praxis, with two key regulatory milestones ahead.”

The company ended the third quarter of 2026 with about $1.3 billion in cash and investments, which it expects to fund operations into 2028. Its net loss widened to $94.2 million from $73.9 million a year earlier, and the company also expects results from its EMERALD trial in the fourth quarter of 2026. Praxis said the relutrigine team is fully hired and that it expects the ulixacaltamide sales force to be in place in the fourth quarter of 2026.

READ NEXT: Cisco (CSCO): Can Software Renewals Outlast the Networking Upgrade Cycle? and Cisco (CSCO): Can Its Earnings Recovery Turn Into Lasting Cash Growth?

Follow Insider Monkey on Google News.

Page 3 of 3